NVAX FY 2012 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

FY 2012 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$22M+50.3% YoY

Gross Profit

$7M33.4% margin

Operating Income

-$30M-134.4% margin

Net Income

-$29M-129.1% margin

EPS (Diluted)

$-4.33

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$23M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$102M

Total Liabilities

$22M

Stockholders' Equity

$80M

Cash & Equivalents

$17M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22M	$15M	+50.3%
Gross Profit	$7M	$8M	-3.9%
Operating Income	-$30M	-$22M	-37.5%
Net Income	-$29M	-$19M	-47.2%